An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Grants Isturisa® (Osilodrostat) Expanded Indication for the Treatment of Enodogenous Hypercortisolemia in Patients with Cushing’s Syndrome On April 15, Recordati announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ISTURISA® (osilodrostat) for...
Recipient of the Endocrine Society’s 2025 Roy O. Greep Award for Outstanding Research, Barbara Kahn, MD, discovered very early on that pursuing basic science could be just as rewarding as treating patients with chronic illnesses. She tells Endocrine News about her career journey, why she relishes working with so many enthusiastic junior scientists, and the...
Last month Corcept Therapuetics Incoporated announced that the U.S. Food and Drug Administration (FDA) filed its New Drug Application (NDA) submission for the company’s proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing’s syndrome). Corcept’s NDA is based on positive results from the pivotal GRACE trial and confirmatory evidence from the Phase 3 GRADIENT...
A recent study entitled “Association Between Per- and Polyfluoroalkyl Substance Exposures and Thyroid Homeostasis Parameters,” published in the Journal of Clinical Endocrinology & Metabolism, has found that exposure to per- and polyfluoroalkyl substances (PFAS) — a group of synthetic chemicals used in industrial and consumer products — may alter thyroid hormone sensitivity, potentially affecting metabolism...
Just when you thought it was time to roll up the red carpet, four Endocrine Society members have recently been announced as taking home their fair share of prestigious awards that recognize outstanding leaders in research and science. First off, the 2025 Breakthrough Prize for Life Science has been presented to Daniel J. Drucker, MD,...
The World Health Organization reports that obesity affects one in eight people globally, making it a major public issue. Yet obesity is not just about diet, exercise, and genes — something else must be afoot. Recently, evidence has pointed to an invisible but powerful culprit: dioxins and dioxin-like polychlorinated diphenyls (DL-PCBs), according to “Association Between...
It is well documented that endocrine-disrupting chemicals (EDCs) are virtually inescapable in everyday life since they are present in everything from food packaging and clothing to flame retardants toys. An upcoming ENDO 2025 session, “Thyroid Disruptors,” examines how EDCs affect thyroid function in pregnancy, childhood, and the link to an increased thyroid cancer risk in...
Doctor AI will see you now — eventually. A new study from The Journal of Clinical Endocrinology & Metabolism has demonstrated how artificial intelligence (AI) can enhance the accuracy of diagnosing Cushing’s syndrome (CS), a rare but serious endocrine disorder caused by excessive cortisol production. Cushing’s syndrome is characterized by a broad spectrum of symptoms,...
Recipient of the Endocrine Society’s 2025 Roy O. Greep Award for Outstanding Research, Barbara Kahn, MD, discovered very early on that pursuing basic science could be just as rewarding as treating patients with chronic illnesses. She tells Endocrine News about her career journey, why she relishes working with so many enthusiastic junior scientists, and the...
